• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Up0.01% Nasdaq Up0.26%

    TapImmune, Inc. (TPIV)

    -Other OTC
    0.58 Down 0.01(0.87%) Nov 25, 3:58PM EST
    ProfileGet Profile for:
    TapImmune, Inc.
    50 North Laura Street
    Suite 2500
    Jacksonville, FL 32202
    United States - Map
    Website: http://www.tapimmune.com

    Index Membership:N/A
    Full Time Employees:1

    Business Summary 

    TapImmune Inc., a clinical-stage immunotherapy company, develops peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer and infectious diseases. The company, in collaboration with Mayo Foundation for Medical Education and Research, is developing HER2/neu, a vaccine technology, which has completed Phase I human clinical trials for the treatment of breast cancer; and Folate Receptor Alpha, a peptide epitope, which has completed Phase I human clinical trials for the treatment of breast and ovarian cancer. Its products under preclinical stage include Polystart, a nucleic acid–based technology for Her2/neu breast cancer, colorectal cancer, ovarian cancer, and triple negative breast cancer. The company was founded in 1999 and is headquartered in Jacksonville, Florida.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on TapImmune, Inc.

    Key Executives 
    Mr. Glynn Wilson Ph.D., 68
    Chairman, Chief Exec. Officer, Pres, Member of Audit Committee and Member of Compensation Committee
    Dr. Robert Z. Florkiewicz Ph.D.,
    Head of Research and Sr. Director of Molecular Biology & Virology
    Mr. Sailesh C. Barchha ,
    Advisor to Board
    Dr. John N. Bonfiglio Ph.D., M.B.A., 61
    Strategic Advisor and Director
    Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders